NSPR INSPIREMD INC

InspireMD to Participate in Upcoming November Investor Conferences

InspireMD to Participate in Upcoming November Investor Conferences

TEL AVIV, Israel and MIAMI, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery disease and prevention of stroke, today announced that the Marvin Slosman, Chief Executive Officer, will participate in three upcoming investor conferences in November:

Wolfe Research Healthcare Conference

Wednesday, November 15, 2023

Fireside chat: 12:30pm ET

Canaccord Genuity MedTech, Diagnostics, Digital Health & Services Forum

Thursday, November 16, 2023

Investor one-on-one meetings only

Piper 35th Annual Healthcare Conference

Wednesday, November 29, 2023

Fireside chat: 8:00am ET

A live webcast of the presentations will be available in the News and Events section of the Company’s website at /en/events/. Replays will be available on the website for 30 days.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR.

We routinely post information that may be important to investors on our website. For more information, please visit .

Investor Contacts:

Craig Shore

Chief Financial Officer

InspireMD, Inc.

888-776-6804

Chuck Padala, Managing Director

LifeSci Advisors

646-627-8390



EN
02/11/2023

Underlying

NSPRINSPIREMD INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INSPIREMD INC

 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial...

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures TOLEDO, Ohio and MIAMI, Feb. 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: NSPR), developer of the CGuard™ Prime Carotid Stent System for the prevention of stroke related to carotid stenosis, and , a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, today announced that, pursuant to a previously strategic outsourcing partnership, the companies are working together to conduct the CGUARDIANS II p...

February 13, 2025 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c...

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, Feb. 04, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to one new non-executive employee in the amount of 18,000 shares of restricted stock outside of InspireMD’s 2021 Equity Compensation Plan, with a grant date as of January 7, 2025, as an inducement material to the employee entering into employment with Insp...

February 4, 2025 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c...

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, Jan. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to nine new non-executive employees in the aggregate amount of 372,135 shares of restricted stock outside of InspireMD’s 2021 Equity Compensation Plan, with a grant date as of January 7, 2025, as an inducement material to the employee entering into employm...

January 21, 2025 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO...

InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025 MIAMI, Dec. 12, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that Craig Shore, Chief Financial Officer, has decided to retire from the Company after a successor CFO is identified and appointed. Mr. Shore will remain as CFO until his successor is appointed and will assist in a smooth and orderly transition. Marvin Slosman, Chief Executive Officer of InspireMD, commented, “Craig has...

December 12, 2024 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD INC

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivota...

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR) Study represents a significant step forward in Company’s mission to serve the broadest set of physician and patient needs with best-in-class CAS and TCAR solutions MIAMI, Dec. 09, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the first patient has been enrolled in the company’s CGUARDIANS ...

December 9, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch